<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 BioMarin Pharmaceutical Rare diseases Orphan drugs Lysosomal storage diseases Glycogen storage disease type II Mucopolysaccharidosis Mannose 6-phosphate Hurler syndrome Phenylketonuria Health Medicine Genetic genealogy |
Add to Reading List |
Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final | How one patient with a rare disease coped with his genetic disorderDocID: 1r9mW - View Document |
| LUMIZYME (alglucosidase alfa) for InjectionDocID: 1qeuI - View Document |
| United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP,DocID: 1oYEH - View Document |
| Pompe disease (Glycogen storage disease type II) Glycogen storage disease type II is also known as acid maltase deficiency or generalized glDocID: 1lJGD - View Document |
| May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to ImDocID: 1aiEg - View Document |